Vital Signs The Analyst's Perspective - August 2015 Issue

Vital Signs The Analyst's Perspective - August 2015 Issue

RELEASE DATE
28-Sep-2015
REGION
Global
Research Code: 9A35-00-3F-00-00
SKU: LS00028-GL-MR_16869

$450.00

Special Price $337.50 save 25 %

In stock
SKU
LS00028-GL-MR_16869

$450.00

$337.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This issue of Vital Signs discusses the FDA's clearnace of the first 3-D printed prescription drug, Illumina's formation of consumer genomics company Helix, Response Genetics' acquisition of Cancer Genetics, and Roche's acquisition of GeneWEAVE.

Table of Contents

Related Research
This issue of Vital Signs discusses the FDA's clearnace of the first 3-D printed prescription drug, Illumina's formation of consumer genomics company Helix, Response Genetics' acquisition of Cancer Genetics, and Roche's acquisition of GeneWEAVE.
More Information
No Index No
Podcast No
Author Christi Bird
WIP Number 9A35-00-3F-00-00
Is Prebook No